Entellus Medical (NASDAQ:ENTL) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Thursday.

Several other research firms also recently commented on ENTL. Zacks Investment Research raised Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Monday, October 9th. Canaccord Genuity reissued a “hold” rating and issued a $17.00 price objective on shares of Entellus Medical in a report on Tuesday, October 17th. Piper Jaffray Companies reissued a “buy” rating and issued a $21.00 price objective on shares of Entellus Medical in a report on Tuesday, August 22nd. Finally, BidaskClub raised Entellus Medical from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. Entellus Medical currently has an average rating of “Hold” and a consensus target price of $20.40.

Entellus Medical (NASDAQ ENTL) opened at $24.35 on Thursday. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. Entellus Medical has a 52 week low of $11.47 and a 52 week high of $24.40.

In other Entellus Medical news, Director Brian E. Farley sold 101,319 shares of the firm’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $23.85, for a total transaction of $2,416,458.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Stephen R. Paidosh sold 25,000 shares of the firm’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $17.54, for a total value of $438,500.00. The disclosure for this sale can be found here. In the last three months, insiders sold 193,469 shares of company stock valued at $4,157,111. 7.70% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its holdings in Entellus Medical by 29.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 40,783 shares of the medical technology company’s stock valued at $675,000 after purchasing an additional 9,270 shares during the last quarter. Nicholas Company Inc. lifted its holdings in Entellus Medical by 1,052.3% during the 2nd quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock valued at $4,101,000 after purchasing an additional 226,190 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in Entellus Medical by 10.5% during the 2nd quarter. William Blair Investment Management LLC now owns 431,187 shares of the medical technology company’s stock valued at $7,140,000 after purchasing an additional 40,853 shares during the last quarter. Wasatch Advisors Inc. lifted its holdings in Entellus Medical by 6.7% during the 2nd quarter. Wasatch Advisors Inc. now owns 231,656 shares of the medical technology company’s stock valued at $3,836,000 after purchasing an additional 14,462 shares during the last quarter. Finally, Archon Capital Management LLC lifted its holdings in Entellus Medical by 34.3% during the 2nd quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock valued at $7,929,000 after purchasing an additional 122,171 shares during the last quarter. 78.76% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Entellus Medical (ENTL) Stock Rating Upgraded by ValuEngine” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/entellus-medical-entl-stock-rating-upgraded-by-valuengine/1753489.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Receive News & Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.